T1	Participants 251 272	patients with cancer.
T2	Participants 427 464	opioid-tolerant patients with cancer.
T3	Participants 567 653	conducted in opioid-tolerant male and female patients (aged > or =17 years) with BTcP.
T4	Participants 1412 1512	131 patients entered the titration phase, of whom 61 were included in the primary efficacy analysis.
T5	Participants 2546 2583	opioid-tolerant patients with cancer.
